The Catalan Institute of Oncology (Institut Català d’Oncologia, ICO) is a public healthcare institution based in Catalonia, Spain, specialised in the prevention, diagnosis, treatment, and research of cancer. Founded in 1995, the ICO holds official accreditation as a Comprehensive Cancer Centre (CCC) by the Organisation of European Cancer Institutes (OECI), representing top-tier European recognition for integrated, multidisciplinary oncology care, research, and training. The institution operates through several hospitals and centres across Catalonia, providing specialised cancer services to a large population within the public healthcare system. Its multidisciplinary teams work in areas such as medical oncology, radiation oncology, haematology, palliative care, cancer epidemiology, and precision medicine. The ICO is strongly committed to scientific research and participates in numerous national and international projects focused on cancer prevention, early detection, personalised therapies, and health equity.
Organisation role in the consortium
ICO contributes its expertise in cancer prevention, public health, health promotion, and evaluation of health outcomes, ensuring that the project’s active mobility interventions are firmly grounded in scientific evidence on cancer prevention and survivorship.
ICO leads Task 1.1 of WP1, providing the scientific evidence on the relationship between active mobility, health, and cancer prevention. It also contributes to WP2 and WP3 (co-designing and implementing Living Lab interventions), to WP4 though the evaluation of health impacts and cross-site assessment of intervention effectiveness, to WP5 through capacity building, policy integration and development of policy recommendations, and to WP7 in terms of ethics and data management.
